Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10278-025004Application No.  
09/753,385**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Michael W. Heartlein et al.Filing Date  
January 3, 2001Group Art Unit  
1646 ✓S


U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
CW	AA	5,416,016	05/16/95	Low et al.	435	240.1	TECH CENTER 1600/2900
	AB	5,292,869	03/08/94	Schryvers	530	413	AUG 15 2001
	AC	5,554,386	06/16/94	Groman et al.	424	488	
	AD	5,154,924	10/13/92	Friden	424	85.91	
	AE	5,182,107	01/26/93	Friden	424	85.91	
	AF	5,527,527	01/15/93	Friden	424	178.1	
	AG	5,672,683	07/16/93	Friden et al.	530	350	
	AH	5,433,946	07/18/95	Allen, Jr. et al.			
	AI	5,447,851	09/05/95	Beutler et al.	435	69.7	04/02/92
	AJ	5,605,690	02/25/97	Jacobs et al.	424	134.1	02/08/95
CW	AK	5,668,255	09/16/97	Murphy			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
CW	AL	WO 91/14438	10/03/91	WIPO			
	AM	WO 92/11383	07/09/92	WIPO			
	AN	WO 95/02421	01/26/95	WIPO			
	AO	WO 93/00917	01/21/93	WIPO			
	AP	WO 93/22450	11/11/93	WIPO			
CW	AQ	WO 93/17038	09/02/93	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CW	AR	Seligman, P., et al., "Molecular Mechanisms of Iron Metabolism", The Molecular Basis of Blood Diseases, p. 219-229 (1987).
CW	AS	Wagner, E., et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," Proc. Natl. Acad. Sci., 87:3410-3414 (1990).
AS	AT	Yan, H., et al., "Chimeric NGF-EGF Receptors Define Domains Responsible for Neuronal Differentiation," Science, 252:561-564 (1991).

Examiner Signature <i>Claudia M. Koff</i>	Date Considered <i>6/16/03</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

AUG 13 2001  
Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10278-025004Application No.  
09/753,385

**Information Disclosure Statement**  
by Applicant  
(Use several sheets if necessary)  
(37 CFR §1.98(b))

Applicant  
Michael W. Heartlein et al.Filing Date  
January 3, 2001Group Art Unit  
1646AUG 15 2001  
TECH CENTER 1600/2900

RECEIVED

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
CW	AU	Hobbs, H.H., et al., "The LDL Receptor Locus in Familial Hypercholesterolemia: Mutational Analysis of a Membrane Protein," Annu. Rev. Genet., 24:133-170 (1990).
	AV	Capon, D.J., et al., "Designing CD4 immunoadhesions for AIDS therapy," Nature, 337:525-531 (1989).
	AW	Traunecker, A., et al., "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules", Nature, 339:68-70 (1989).
	AX	Wagner, E., et al., "Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis", Advanced Drug Delivery Reviews, 14:113-135 (1994).
	AY	Styles, et al., "Rat monoclonal antibodies to the external domain of the product of the c-erbB-2 proto-oncogene," Int.J. Cancer, 45:320-324 (1990).
	AZ	Shin, et al., "Transferrin-antibody fusion proteins are effective in brain targeting," Proc. Natl. Acad. Sci., USA, 92:2820-2824 (1995).
CW	AAA	Parise et al., "Construction and in vitro Functional Evaluation of a Low-Density Lipoprotein Receptor/ Transferrin Fusion Protein as a Therapeutic Tool for Familial Hypercholesterolemia" Human Gene Therapy 10: 1219-1228 (1999).

Examiner Signature

Date Considered

6/16/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.